12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 1d ago
Gainers
- Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 during Wednesday's regular session. The company's market cap stands at $1.1 million.
- Vor Biopharma (NASDAQ:VOR) shares moved upwards by 58.75% to $0.51. The company's market cap stands at $39.7 million.
- GlucoTrack (NASDAQ:GCTK) shares increased by 33.07% to $8.26. The company's market cap stands at $3.5 million.
- VYNE Therapeutics (NASDAQ:VYNE) stock moved upwards by 33.01% to $1.41. The company's market cap stands at $17.6 million.
- Anbio Biotechnology (NASDAQ:NNNN) shares moved upwards by 30.93% to $31.53. The company's market cap stands at $1.0 billion.
- Nektar Therapeutics (NASDAQ:NKTR) stock increased by 26.86% to $31.02. The market value of their outstanding shares is at $303.3 million.
Losers
- Annovis Bio (NYSE:ANVS) stock declined by 26.1% to $2.26 during Wednesday's regular session. The market value of their outstanding shares is at $59.6 million.
- Forte Biosciences (NASDAQ:FBRX) stock decreased by 25.69% to $10.53. The market value of their outstanding shares is at $93.2 million.
- OneMedNet (NASDAQ:ONMD) stock fell 25.2% to $0.51. The market value of their outstanding shares is at $20.8 million.
- Bone Biologics (NASDAQ:BBLG) stock decreased by 21.14% to $4.38. The market value of their outstanding shares is at $3.0 million.
- Know Labs (AMEX:KNW) stock declined by 17.65% to $2.1. The company's market cap stands at $18.9 million.
- Concord Medical Services (NYSE:CCM) shares declined by 15.93% to $4.91. The market value of their outstanding shares is at $253.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.